BioSpace News Archive

Flood in geriatric populace, ascend in predominance of constant respiratory infections, and expansion in government uses on medical services drive the development of the U.S. Portable ventilator market.

Valneva SE today announced the initiation of a further Phase 3 trial (VLA2001-304) for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

BioVie Inc. today announced the closing of its underwritten public offering of 2,500,000 shares of its Class A common stock at a public offering price of $8.00 per share

Be Biopharma today announced that Krishnan Viswanadhan, Pharm.D., MBA, has been appointed President and Chief Operating Officer and Brad Hartman has joined as Chief People Officer.

BioRestorative Therapies, Inc. today reminded its stockholders that its annual meeting of stockholders will be held on Tuesday, August 17, 2021 at 10 a.m. EDT.

Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases.

Skymount Medical, a drug discovery company, and Louisiana State University (LSU) announced today that human studies have begun on its unique combination of therapies, known as SM-19, for COVID-19 patients.

Lucia Health Guidelines, a company applying machine learning at the point of care in the treatment of atrial fibrillation (AFib), today announced the publication of its AIM-HIGHER proof-of-concept study in the Journal of the American College of Emergency Physicians (JACEP) Open.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today highlights recent findings from North Carolina State University, that its new treatment for mast cell cancers, known as HT-KIT, reduces the number of mast cells by “mutating” the messenger RNA (mRNA) before it can deliver instructions for manufacturing the gene responsible for cell proliferation.

Samsung NeuroLogica Corp. today announced that it received the Risk Management Framework approval, Authority to Operate (ATO) from the Defense Health Agency for its RS85 Prestige Ultrasound.